"God created all diseases except GvHD, that we created" Hillard Lazarus Transplanters carry guilt of poor patient outcomes and NRM. The type of cGVHD 👇 reminds me why I vowed NEVER to use tac/mtx again. With ptCY & other data IMO it is no longer acceptable. #GvHD #alloHCT

Answer: T-LGL clone. Often donor in origin - Associated with neutropenia. - Can be clonal - rule out viral reactivations (EBV, CMV etc) - I often treat (in neutropenics) 60mg pred x 10-14days [no taper] In this patients, post pred the clonal T-LGL diappeared

❓Quiz ⏲️⏲️: 68yr old MDS patient day +167 post ptCY-based matched Allo HCT. No #GvHD - On 0.5mg of tacrolimus - CBC showed WBC of 2.0; platelets 204. ANC 600/uL - On exam no adenopathy - T-cell chimerism fully donor - PB flow shown below Diagnosis & Rx?? #bmtsm Allo 🦪

People wonder why physicians #burnout Evidence below: Plus do you are expected to do more: - research - administration - teaching - nonsense satisfaction score (FYI patients want doctors to talk to them. How do you do that when you are double triple booked???)

Current status of ADCs in #lymphoma #DLBCL. Loved developing this invited piece with two lymphoma rising stars @gulrayzahmed & @Taha_CancerDoc @MCWCancerCenter #lymsm www.tandfonline.com/doi/full/10....

Our @BMTCTN 1506 deep drive on FLT3 MRD and #alloHCT #AML @BloodJournal -15% have micro-clones = worse RFS -MRD+ relapse with WT or with clones persisting (can monitoring in tailor duration?) -if u eradicate MRD, u r fine -Some micro-clones survive and strike if gilt stops

Our new @BMTCTN 1703 analysis busts a few myths: - QOL improved with ptCY - 🩸Cystitis not worse - 2yr GRFS superior 42% vs 29%, p=0.001 - ptCY relapse NOT higher @sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT ascopubs.org/doi/10.1200/...

Playoff clinched @packers #GoPackGo

Pink ODI for #breastcancer awareness 🇵🇰 vs. 🇿🇦 #GoPakGo @LubnaChaudhary1 🏏

Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis. Recently saw my city #Lahore (Pakistan) and nearby #NewDehli breaking air pollution records ashpublications.org/blood/articl...

Love seeing the Nivo-AVD story in older patients grow in Frontline c Hodgkin Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... congrats @PallawiTorkaMD Need effective tools is frail/unfit/super elderly #lymsm

Safety and Efficacy of Glofitamab for DLBCL in RW. It works, but like nearly all drugs, works less well in the streets #lymsm ashpublications.org/bloodadvance...

Impressive results of Dara vs. W&W in Smoldering #myeloma. Delay in progression; 📉mortality risk, favorable AE profile. ✅ Checks all the 📦📦 (just because HR SMM does not meet MM definition, doesn't mean it is not a PCD) congrats @vincentrk.bsky.social et al. www.nejm.org/doi/full/10....

CD19.20 dual CAR in third or later line DLBCL being presented by @niravshahmd #ASH24

I can see the convention center #ASH24

First selfie of #ASH24 with none other than @medihumdani.bsky.social 🩸 We are on our way to San Diego from Milwaukee! @ash-hematology.bsky.social

Severe aplastic anemia. ASTCT guidelines 2024 www.astctjournal.org/article/S266...

Much awaited ECOG 4151 results out. IMO definitely ends debate for autoHCT in MCL in MRD negative CR1. #PracticeChaning and congrats to my friend @timfenske in advancing patient care @MCWCancerCenter @ASH_hematology #ASH2025 ash.confex.com/ash/2024/web...

Go Pack Go @gbpackers.bsky.social

University of Bologna, oldest in the world and its iconic Anatomical Theatre

Super interesting real world study showing superiority of Axi-cel over liso-cel after matching. Off trial, I uniformly use axi-cel regardless of patient characteristics. IMO reliability and turn around matters!! #lymsm ashpublications.org/bloodadvance...

@szusmani.bsky.social At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,

Impressive 3-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies. Median PFS 24mons, median OS NR #lymsm ashpublications.org/blood/articl...

🚨Capstan Therapeutics Preclinical Data on In Vivo CAR-T -engineering of CD8+ CAR T cells, profound B cell depletion in blood & tissues, repopulation w predominantly naïve B cells in NHP's -without need for lymphodepleting chemotherapy -plans to clinic mid 2025 www.capstantx.com/posts/capsta...

Saad Usmani, MD, shared exciting FIRST results from CEPHEUS study of a Dara quad in transplant-ineligible/transplant-deferred NDMM. Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24

Packers aka Bear owners

WNDR Chicago